Results 11 to 20 of about 6,174 (184)

Successful response in advanced leptomeningeal disease from pleomorphic xanthoastrocytoma with BRAF/MEK inhibitors: a case report [PDF]

Frontiers in Oncology
Leptomeningeal disease (LMD) is a rare metastatic complication with a grim prognosis for most patients and limited treatment strategies. Therapy is adjusted to the primary tumor from which it arises.
Maria A. Jacome, Robert J. Macaulay, Edwin Peguero, Sheethal Cyriac, Solmaz Sahebjam, Arnold B. Etame, Hsiang-Hsuan Michael Yu, Yolanda Piña, Yolanda Piña   +8 more
doaj   +2 more sources

Antitumor effects of immunotherapy combined with BRAF and MEK inhibitors in BRAF V600E metastatic colorectal cancer [PDF]

Cancer Immunology, Immunotherapy
BRAF-mutated colorectal cancer correlates with poor prognosis and limited response to standard treatments. Combining immune checkpoint inhibitors with BRAF/MEK inhibitors shows promise against BRAF-mutant melanoma in both preclinical and clinical trials.
Eunyoung Tak, Hye-In An, Amy Sinyoung Lee, Kyuyoung Han, Jiwan Choi, Hyung-don Kim, Yong Sang Hong, Sun Young Kim, Eun Kyung Choi, Jeong Eun Kim, Tae Won Kim   +10 more
doaj   +2 more sources

An Evaluation of the Drug Interaction Potential of Encorafenib in Combination With Binimetinib Using the Inje Cocktail in Patients With Cancer. [PDF]

Clin Pharmacol Ther
A clinical drug–drug interaction (DDI) study was designed to evaluate the effect of single and multiple oral doses of encorafenib on the single oral dose pharmacokinetics (PK) of the cytochrome P450 (CYP) enzyme probe substrates, losartan (CYP2C9), midazolam (CYP3A4), caffeine (CYP1A2), omeprazole (CYP2C19), and dextromethorphan (CYP2D6) administered ...
Piscitelli J, Reddy MB, Wollenberg L, Del Frari L, Gong J, Matschke K, Williams JH.   +6 more
europepmc   +2 more sources

Cost-effectiveness analysis of encorafenib and binimetinib combination as first-line treatment for metastatic or unresectable BRAF V600-mutated metastatic melanoma in Russia

Фармакоэкономика, 2023
Objective: to perform a cost-effectiveness analysis of using encorafenib and binimetinib combination in the first-line therapy for metastatic or unresectable BRAF V600-mutated melanoma in the Russian Federation. Material and methods.
N. A. Avxentyev, Yu. V. Makarova
doaj   +1 more source

Case Report: Combined CDK4/6 and MEK Inhibition in Refractory CDKN2A and NRAS Mutant Melanoma

Frontiers in Oncology, 2021
There are only limited treatment options for metastatic NRAS mutant melanoma patients with resistance to immune checkpoint inhibitors. Besides activation of the mitogen-activated protein (MAP) kinase pathway, they often have additional disturbances in ...
Andrea Forschner, Tobias Sinnberg, Tobias Sinnberg, Gabi Mroz, Christopher Schroeder, Christian Philipp Reinert, Sergios Gatidis, Michael Bitzer, Thomas Eigentler, Claus Garbe, Heike Niessner, Martin Röcken, Martin Röcken, Cristiana Roggia, Sorin Armeanu-Ebinger, Olaf Riess, Olaf Riess, Sven Mattern, Dominik Nann, Irina Bonzheim   +19 more
doaj   +1 more source

A phase Ib trial of combined PKC and MEK inhibition with sotrastaurin and binimetinib in patients with metastatic uveal melanoma

Frontiers in Oncology, 2023
BackgroundUveal melanoma is a disease characterized by constitutive activation of the G alpha pathway and downstream signaling of protein kinase C (PKC) and the mitogen-activated protein kinase (MAPK) pathway.
Sebastian Bauer, James Larkin, F. Stephen Hodi, Frank Stephen, Frank Stephen, Ellen H. W. Kapiteijn, Gary K. Schwartz, Emilano Calvo, Padmaja Yerramilli-Rao, Sophie Piperno-Neumann, Richard D. Carvajal   +10 more
doaj   +1 more source

Melanoma: Pathogenesis and Targeted Therapy. [PDF]

MedComm (2020)
The treatment landscape for advanced melanoma has evolved significantly. BRAF–MEK inhibitor combinations are standard for BRAF‐mutant melanoma, whereas targeting NRAS mutations is more challenging, with MEK inhibitors like tunlametinib emerging as an option.
Fu Y, Liu J, Mo Z, Wang B, Deng Y, Jiang Y.   +5 more
europepmc   +2 more sources

Measurement and models accounting for cell death capture hidden variation in compound response. [PDF]

, 2020
Cancer cell sensitivity or resistance is almost universally quantified through a direct or surrogate measure of cell number. However, compound responses can occur through many distinct phenotypic outcomes, including changes in cell growth, apoptosis, and
Bae, Song Yi, Guan, Ning, Meyer, Aaron S, Taylor, Scott D, Warner, Katrina, Yan, Rui   +5 more
core   +1 more source

A Validated LC–MS/MS Assay for the Simultaneous Quantification of the FDA-Approved Anticancer Mixture (Encorafenib and Binimetinib): Metabolic Stability Estimation

Molecules, 2021
The concurrent use of oral encorafenib (Braftovi, ENF) and binimetinib (Mektovi, BNB) is a combination anticancer therapy approved by the United States Food and Drug Administration (USFDA) for patients with BRAFV600E/V600K mutations suffering from ...
Mohamed W. Attwa, Hany W. Darwish, Nasser S. Al-Shakliah, Adnan A. Kadi   +3 more
doaj   +1 more source

BRAF and MEK Inhibitors and Their Toxicities: A Meta-Analysis [PDF]

, 2023
Purpose: This meta-analysis summarizes the incidence of treatment-related adverse events (AE) of BRAFi and MEKi. Methods: A systematic search of Medline/PubMed was conducted to identify suitable articles published in English up to 31 December 2021.
Bergnach M., Garutti M., Palmero L., Pizzichetta M. A., Polesel J., Puglisi F.   +5 more
core   +4 more sources